Malad Escorts, (Pooja 09892124323), Malad Call Girls Service
IntelGenx March 13, 2017 Investor Presentation
1. 0
TSX-V: IGX
OTCQX: IGXT
WE MAKE APPROVED DRUGS BETTER
Investor Presentation
March 10, 2017
Innovative Drug Delivery Solutions
2. 1
2
To the extent any statements made in this presentation contain information that is not historical, these statements are forward-
looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and
projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-
looking statements.
Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and
other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future
events or circumstances are forward-looking statements. Forward-looking statements include, but are not necessarily limited to,
risks and uncertainties, including the difficulty of predicting U.S. Food and Drug Administration and Canadian Therapeutic
Products Directorate approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products
and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished
products, the regulatory environment, tax rate assumptions, the outcome of legal proceedings, fluctuations in operating results
and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission and the
Ontario Securities Commission. IntelGenx undertakes no obligation to update or revise any forward-looking statement.
2
Forward Looking Statements
4. 3
4
Advantages of Oral Thin Film Delivery
We are focused on areas where oral films
are particularly well-suited:
Develop and commercialize products that provide therapeutic advantages to patients
leveraging oral films, such as:
• Reduced side effects
• Improved bio-availability
• Response time versus existing drugs
• Lifecycle management
• Repurpose existing drugs for new indications using oral films
• “First-to-file” Generic drugs where high technology barriers to
entry exist in reproducing branded films
5. 5
Clearly Defined BD Strategy
Balancing Risks and Opportunities for an Optimized Portfolio
Overall
Risk
Time to MarketSlow Fast
Low
High
Drug Repurposing
Patient Benefits
Lifecycle Mgmt
FTF Generics
IntelGenx Future Focus
Deal Value
Low
Medium
High
6. 5
A Robust Product Pipeline
to Address Significant Market Opportunities
6
7. 6
7
• High dose version of Wellbutrin XL®
• Only approved, once-daily, bupropion HCl 450mg dose in a
single tablet
• Launched commercially October 2013 in partnership with
Edgemont Pharmaceuticals
• Sold US revenue to SWK Holdings for US$6M
• Development cost $2.5M, total revenue $15M = 6-fold ROI
• Non-dilutive source of funding, will be used to advance film
projects
Successful Monetization of First
In-House Development
8. 7
8
• Licensing and development agreements entered for four
generic products
• IntelGenx granted Chemo exclusive worldwide license to
commercialize two generic tablets and U.S. license for two
other generic oral films
• IntelGenx to receive upfront, milestone, R&D revenues and
share of profits – total value of 7 digits
• Combined total market of four products is over $7B
• Chemo making a strategic move into novel drug delivery
products with IntelGenx as its partner
• Partnership could result in numerous future product
agreements
Strategic Partnership with Chemo Group
About Chemo Group:
• Founded in 1978
• 5,000 employees
• Head office in Spain
• Revenues of $1.2B annually
• Markets over 300 products
• Operating in over 40 countries
• 20 state-of-the-art facilities
• 9 specialized R&D centers
9. 8
For Migraines
Leverages VersaFilm™ Technology
VersaFilm
TM
Rizaport
9
• European Mktg Approval – November 2015
• Co-development partnership with RedHill Biopharma
• Definitive agreement signed July 2016 with
Grupo Juste for Spain & additional territories
• Definitive agreement signed Dec 2016 with Pharmatronic
for South Korea
• Actively pursuing several opportunities to open new markets
- negotiations with future commercialization partners
ongoing
• Planned USA submission to FDA Q3/17
• Expected USA approval Q1/18
10. 9
For Erectile Dysfunction
VersaFilm
TM
Tadalafil
• Will allow entry of Tadalafil VersaFilm™ into
the ED US market upon FDA approval,
potentially before the market entry of Cialis®
generic competitors
• Accelerates our partnering of this product
• Containing tadalafil (Cialis® - Eli Lilly),
a leading molecule in the ED market
• Demonstrated bioequivalence to Cialis®
• Orally disintegrating films without need for
water provide unprecedented patient
convenience and a discrete dosing alternative
• 505(b)(2) USA NDA submission in Q2/17
• Expected USA approval H1/2018
VersaFilm
TM
Tadalafil
10
Granted license from Lilly for Tadalfil ED dosing
patent ‘166
11. 10
For Schizophrenia & Bipolar
1 Disorder
11
• The first oral thin film using IntelGenx
proprietary drug delivery technology,
VersaFilm™, for treatment of schizophrenia
& bipolar 1 disorder
• Fast-acting loxapine oral dosage – to treat
acute agitation and anxiety in non-
institutionalized patients with schizophrenia
& bipolar 1 disorder
• Reduces risk of pulmonary problems
and potential risk of violence and injury to
patients and others
• Formulation optimization stage – results
expected H2 2017
VersaFilm
TM
Loxapine
VersaFilm
TM
Loxapine
12. 11
For Brain Degenerative Diseases
VersaFilm
TM
Montelukast
12
VersaFilm
TM
Montelukast
• IntelGenx is repurposing Montelukast
for the treatment of brain degenerative diseases by
leveraging its VersaFilm™ technology
• The drug is known and approved for a completely
different indication (asthma)
Global Sales for AD by Patients Category (Global
Data, 2013)
13. 12
2
13
Clinical Data
0.0
100.0
200.0
300.0
400.0
500.0
600.0
0.00 5.00 10.00 15.00 20.00 25.00 30.00
Montelukastconcentration(ng/mL)
Time (hrs)
Montelukast Avg Plasma Profile
Test buccal film 10mg
Ref tablet 10mg
VersaFilm
TM
Montelukast
• Phase 1 clinical study in human successfully completed
• Significantly increased bioavailability after administration of VersaFilm compared to
commercial tablet
• Drug crosses blood/brain barrier when given as film
• Phase II-a study (proof of concept) to commence Q1/17
• First efficacy data in humans available Q4/17
• Several Pharma companies have expressed strong interest
Before
MMSE 13:
moderate to severe
dementia
MMSE 22:
mild dementia
After 2 Months of
Montelukast
14. 13
14
Construction of Manufacturing Facility Completed
• 17,000 sq ft facility in Montreal -
construction completed in Q1 2016
• Facility to be fully operational by Q1 2017
• High capacity manufacturing and packaging
equipment
• Lower costs, controls quality
and de-risks investment
for new products
GROSS MARGINS of 40% PLUS
We have built a state-of-the-art
oral film development and manufacturing facility
15. 14
Strengthened Management Team
Over 30 Employees, including 7 with Ph.D.’s
Andre Godin, CPA, CA
Executive VP, CFO
• 25+ years biotech/pharma
industry experience
• Member of the Canadian
Chartered Professional
Accountants and the Canadian
Institute of Chartered
Accountants
Nadine Paiement, M. Sc.
VP, Research & Development
• Co-inventor of IntelGenx
Trilayer Technology
• 15 years experience in product
development and technology
transfer
Horst G. Zerbe, Ph. D.
Chairman, President & CEO
• Co-Founder of Listerine breath
strips
• 30+ years drug delivery /
pharma experience
• Holds over 40 patents in drug
delivery and numerous scientific
publications
15
Dana Matzen, Ph.D.
VP, Business & Corporate
Development
• 15 years experience in
pharmaceutical product licensing
• Prev. Director, BD at Paladin
• Completed 13 transaction,
7 new product launches
John Durham, B. Sc.
VP, Operations
• 20+ years experience in
pharmaceutical manufacturing,
quality management, product
development
• Held executive positions with
several Canadian and US
companies
16. 15
16
The IntelGenx Advantage
1. History
• Dr. Zerbe a pioneer with over 30 plus years in oral films
2. Formulation Team
• Strong in applying biopharmaceutical aspects to formulation development
• Top quality scientists: highly creative, focused on problem solving & innovative approaches
• Experienced in developing films for oral (GI), sublingual & buccal absorption
3. Clearly Defined Corporate Strategy And Business Model
• Focus on drug repurposing, lifecycle management, patient benefits, and FTF
• Provider of comprehensive pharmaceutical services to industry partners
4. Competitive Manufacturing Capabilities
• First in Canada
• New state-of-the-art manufacturing facility
• Offer one-stop-shopping to our partners with lean operations keeping costs down
• Customized manufacturing equipment
19. 18
Net Comprehensive Income & Adjusted EBITDA ($M)
-1.5
0.6
0.8
-2.2
-0.9
1.3
1.7
-1.6
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
1.5
2
First 9 mths 2016 First 9 mths 2015 2015 Full Year 2014 Full Year
Net Income Adjusted EBITDA
$M
Financial Performance
19
21. 20
21
Solid Platform for Growth
Significant Market Potential
• New manufacturing facility will offer many competitive advantages
• Strengthened management team to accelerate execution of business plan
• Implemented product sourcing strategy to identify high-value product opportunities
• Building strategic partnerships with relevant partners in the pharmaceutical industry
Solid Platform for Growth
